Has the Clinical Profile of Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban Changed in the Last 5 Years of use?

Abstract

Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban. Methods: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012–December 2013 and January 2014–January 2017). Results: 211 patients (mean age 76.7 ± 9.2 years; CHA₂DS₂-VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively. Conclusion: Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.

Keywords: :

• atrial fibrillation
• clinical practice
• clinical profile
• rivaroxaban
• ROCKET-AF

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing assistance was provided by Content Ed Net (Madrid, Spain) with funding from Bayer Hispania.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.